The recommended dosing schedule for PEMGARDA involves an initial single intravenous infusion of 4500 mg, followed by repeat doses of 4500 mg administered every three months to maintain continuous passive immune protection. Timelines for repeat infusions are calculated precisely from the date of the most recent administration under the supervision of a qualified healthcare professional. Regular adherence to this quarterly dosing interval is essential for sustaining protective monoclonal antibody levels in the bloodstream of vulnerable, immunocompromised patients.